NEW YORK (GenomeWeb) – Cynvenio Biosystems today announced the launch of an early access program for its LiquidBiopsy Rare Cell Isolation Platform.
The Mayo Clinic Cancer Center and the Norris Comprehensive Cancer Center, part of the Keck School of Medicine at the University of Southern California, are the first centers to participate in the program, which allows cancer research laboratories to have direct, on-site access to genomic material from highly purified cell populations for analysis. The LiquidBiopsy platform automates the identification and enrichment of rare tumor cells from standard patient blood draws, and delivers ultra-high sample purity for next-generation sequencing, PCR, expression analysis, fluorescent in situ hybridization, and immunohistochemistry.
The platform, Cynvenio added, can detect as few as one target cell per milliliter. Its technology has been available as a CLIA lab service to doctors and pharmaceutical firms since 2013, Cynvenio CEO André de Fusco said. "Our goal for the new LiquidBiopsy platform program is to enable those at the forefront of cancer research to unlock the complexities of tumor heterogeneity, concordance between sample types, and longitudinal patient monitoring," he said in a statement.